These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8846242)

  • 21. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case management of the anemic patient. Epoetin alfa: focus on hematocrit.
    Kirlin L
    ANNA J; 1992 Feb; 19(1):66-7. PubMed ID: 1546890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.
    Bacchus S; O'Mara N; Manley H; Fishbane S
    Ann Pharmacother; 2009 Nov; 43(11):1857-66. PubMed ID: 19826095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
    Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
    Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits.
    Gilmartin C
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S15-22; quiz S23-5. PubMed ID: 17591991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epoetin alfa: focus on inflammation and infection. Case study of the anemic patient.
    Chambers JK
    ANNA J; 1998 Jun; 25(3):353-6. PubMed ID: 9801493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case management of the anemic patient. Epoetin alfa: focus on quality of life.
    Butera E
    ANNA J; 1992 Aug; 19(4):410-1. PubMed ID: 1520032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
    Wright DG; Wright EC; Narva AS; Noguchi CT; Eggers PW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1822-30. PubMed ID: 26358266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing anemia using laboratory trend analysis. Case study of the anemic patient.
    Aiello J
    ANNA J; 1999 Aug; 26(4):430-3. PubMed ID: 10838975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of a clinical pharmacy anemia management service on adherence to monitoring guidelines, clinical outcomes, and medication utilization.
    Debenito JM; Billups SJ; Tran TS; Price LC
    J Manag Care Spec Pharm; 2014 Jul; 20(7):715-20. PubMed ID: 24967524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case study of the anemic patient: epoetin alfa--focus on CQI and patient management.
    Kammerer JK
    ANNA J; 1994 Aug; 21(5):282-5. PubMed ID: 8080342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case study of the anemic patient: epoetin alfa--focus on inflammation.
    Fuchs J
    ANNA J; 1994 Feb; 21(1):78-81. PubMed ID: 8141637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.